coronary artery disease - Drug eluting stent - unparticular patients clinical trials results meta-analysis

<h1> <a href="index.html"> <strong>coronary artery disease</strong> - Drug eluting stent </a> - unparticular patients trial results systematic overview and meta-analysis </h1> <h2>Main characteristics of the included studies</h2> <table> <tr> <th>Trial</th> <th>Treatments</th> <th>Patients</th> <th>Methods</th> </tr> <tr> <td> <a href="index.html"> Kochiadakis, 2007 </a> <br> </td> <td> sirolimus-eluting stents<br>  <i>versus</i> <br> bare metal stent </td> <td> one-vesseldisease (>70% narrowing of the lumen of one major epicardialcoronary artery); stable coronary artery disease, age <70 years, and vessel referencediameter >=2.5 mm </td> <td> follow-up 4.8 months (mean)<br> n=38/43<br> Parallel groups<br> open <br> Greece </td> </tr> <tr> <td> <a href="index.html"> RAVEL, 2002 </a> <br> NCT00233805 </td> <td> coated Bx Velocity<br>  <i>versus</i> <br> Bx Velocity </td> <td> Stable or unstable AP, silent ischaemia; single primary target lesion in a native coronary artery </td> <td> follow-up 12 months<br> n=120/118<br> Parallel groups<br> double-blind <br> Global </td> </tr> <tr> <td> <a href="index.html"> SIRIUS, 2003 </a> <br> NCT00232765 </td> <td> SES<br>  <i>versus</i> <br> Bx Velocity </td> <td> Stable or unstable AP, signs of myocardial ischaemia </td> <td> follow-up 9 months<br> n=533/525<br> Parallel groups<br> double-blind <br> United States </td> </tr> <tr> <td> <a href="index.html"> C-SIRIUS, 2004 </a> <br> NCT00381420 </td> <td> coated Bx-VELOCITY<br>  <i>versus</i> <br> Bx-VELOCITY </td> <td> Stable or unstable AP, silent ischaemia </td> <td> follow-up 9 months<br> n=50/50<br> Parallel groups<br> double-blind <br> Canada </td> </tr> <tr> <td> <a href="index.html"> E-SIRIUS, 2003 </a> <br> NCT00235144 </td> <td> coated Bx Velocity<br>  <i>versus</i> <br> Bx Velocity </td> <td> Stable or unstable AP, silent ischaemia; single-vessel or multivessel coronary disease but with only one new lesion with an estimated stenosis of more than 50% but less than 100% in a major native coronary artery requiring treatment </td> <td> follow-up 9 months<br> n=175/177<br> Parallel groups<br> open <br> Europe </td> </tr> <tr> <td> <a href="index.html"> TAXUS I, 2003 </a> <br> </td> <td> TAXUS NIR<br>  <i>versus</i> <br> NIR stent </td> <td> Stable or unstable AP, silent ischaemia; single de novo or restenotic coronary lesions </td> <td> follow-up 12 months<br> n=31/30<br> Parallel groups<br> double-blind <br> Germany </td> </tr> <tr> <td> <a href="index.html"> TAXUS II, 2003 </a> <br> NCT00299026 </td> <td> TAXUS<br>  <i>versus</i> <br> NIR stent </td> <td> Stable or unstable AP, silent ischaemia; single de novo target lesion with estimatedstenosis >50% and <99%, </td> <td> follow-up 12 months<br> n=266/270<br> Parallel groups<br> double-blind <br> Global </td> </tr> <tr> <td> <a href="index.html"> TAXUS IV, 2004 </a> <br> NCT00292474 </td> <td> TAXUS<br>  <i>versus</i> <br> EXPRESS </td> <td> Stable or unstable AP, provokable ischaemia with a single, previously untreated coronary-artery stenosis (vessel diameter, 2.5 to 3.75 mm; lesion length, 10 to 28 mm) </td> <td> follow-up 9 months<br> n=662/652<br> Parallel groups<br> double-blind <br> United States </td> </tr> <tr> <td> <a href="index.html"> ASPECT, 2003 </a> <br> NCT00196079 </td> <td> coated Supra-G stent<br>  <i>versus</i> <br> Supra-G stent </td> <td> patientswith discrete coronary lesions (<15 mm in length, 2.25 to 3.5 mm in diameter) </td> <td> follow-up 6 months<br> n=117/58<br> Parallel groups<br> double-blind <br> NA </td> </tr> <tr> <td> <a href="index.html"> ELUTES, 2004 </a> <br> </td> <td> coated V-Flex Plus<br>  <i>versus</i> <br> V-Flex Plus </td> <td> single de novo type A or type B1 lesions 15 mm length in a nativecoronary artery </td> <td> follow-up 12 months<br> n=152/38<br> Parallel groups<br> open <br> Europe </td> </tr> <tr> <td> <a href="index.html"> DELIVER, 2004 </a> <br> </td> <td> non-polymer-based paclitaxel-coated ACHIEVE stent<br>  <i>versus</i> <br> stainless steel Multi-Link (ML) PENTA stent </td> <td> patients with focal de novo coronary lesions, <25 mm in length, in 2.5- to 4.0-mm vessels </td> <td> follow-up 9 months<br> n=524/519<br> Parallel groups<br> single-blind <br> US </td> </tr> <tr> <td> <a href="index.html"> PATENCY, 2002 </a> <br> </td> <td> Logic PTX paclitaxel Eluting CoronaryStents<br>  <i>versus</i> <br> uncoated control stents </td> <td> Patients with de novo lesions of 2.7- to 4.0-mm diameter and 25-mm length received 3.0, 3.5, or 4.0 mm 10- or 15-mm </td> <td> follow-up 9 months<br> n=24/26<br> Parallel groups<br> double blind <br> </td> </tr> <tr> <td> <a href="index.html"> SCORE, 2004 </a> <br> </td> <td> QuaDDS stents (paclitaxel)<br>  <i>versus</i> <br> uncoated control stents </td> <td> patients with focal, de novo coronary lesions </td> <td> follow-up 12 months<br> n=126/140<br> Parallel groups<br> open <br> Worldwide </td> </tr> <tr> <td> <a href="index.html"> ACTION, 2004 </a> <br> </td> <td> Multilink Tetra stent<br>  <i>versus</i> <br> uncoated Multilink Tetra stent </td> <td> Patients with stable angina pectoris orsilent ischemia and a single de novo lesion in a nativecoronary artery >=3.0 mm and <=4.0 mm in diameter thatcould be covered by an 18-mm stent </td> <td> follow-up 6 months<br> n=241/119<br> Parallel groups<br> single-blind <br> worldwide </td> </tr> <tr> <td> <a href="index.html"> FUTURE I, 2004 </a> <br> </td> <td> everolimus coated S-Stent<br>  <i>versus</i> <br> S-Stent </td> <td> de novo coronary lesions </td> <td> follow-up 12 months<br> n=27/15<br> Parallel groups<br> single-blind <br> Germany </td> </tr> <tr> <td> <a href="index.html"> FUTURE II, 2006 </a> <br> </td> <td> CHAMPION<br>  <i>versus</i> <br> bare-metal stent </td> <td> Patients with de novo lesions in vessels with a reference diameter of 2.75-4.0 mm and length  </td><td> follow-up 6 months<br> n=43/21<br> Parallel groups<br> double-blind <br> NA </td> </tr> <tr> <td> <a href="index.html"> Pache et al, 2005 </a> <br> </td> <td> Cypher<br>  <i>versus</i> <br> BeStent 2 </td> <td> with symptomatic coronary artery disease and significant angiographic stenosis in native coronary vessels </td> <td> follow-up 12 months<br> n=250/250<br> Parallel groups<br> open <br> Germany </td> </tr> <tr> <td> <a href="index.html"> Ortolani et al, 2007 </a> <br> </td> <td> Cypher<br>  <i>versus</i> <br> Vision </td> <td> symptomatic coronary artery disease and target vessel diameter appropriate for implantation a 3-mm stent </td> <td> follow-up 9 months<br> n=-9/-9<br> Parallel groups<br> single-blind <br> </td> </tr> <tr> <td> <a href="index.html"> TAXi, 2005 </a> <br> </td> <td> Cypher<br>  <i>versus</i> <br> Taxus </td> <td> Unselected patients </td> <td> follow-up 6 months<br> n=102/100<br> Parallel groups<br> open <br> Switzerland. </td> </tr> <tr> <td> <a href="index.html"> SIRTAX (Windecker), 2005 </a> <br> </td> <td> sirolimus-eluting stents (Cypher)<br>  <i>versus</i> <br> paclitaxel-eluting stents (Taxus) </td> <td> Unselected patients. Stable AP, ACS, including AMI. at least one lesion with stenosis of at least 50 percent in a vessel with a reference diameter between 2.25 and 4.00 mm that was suitable for stent implantation </td> <td> follow-up 9 mo (5y)<br> n=503/509<br> Parallel groups<br> single-blind <br> Switzerland </td> </tr> <tr> <td> <a href="index.html"> REALITY, 2006 </a> <br> NCT00235092 </td> <td> Cypher<br>  <i>versus</i> <br> Taxus </td> <td> Relatively unselected patients. Stable or unstable documented silent ischaemia, no AMI with 1 or 2 de novo lesions (2.25-3.00 mm in diameter) in native coronary arteries </td> <td> follow-up 12 months<br> n=701/685<br> Parallel groups<br> open <br> Europe, Latin America, and Asiam </td> </tr> <tr> <td> <a href="index.html"> Zhang (SES vs PES), 2006 </a> <br> </td> <td> Cypher<br>  <i>versus</i> <br> Taxus </td> <td> Unselected patients. Stable or unstable AP, ACS with de novo coronary lesions </td> <td> follow-up 1y<br> n=246/203<br> Parallel groups<br> open <br> China </td> </tr> <tr> <td> <a href="index.html"> SORT OUT II, 2008 </a> <br> NCT00388934 </td> <td> Cypher stent<br>  <i>versus</i> <br> Taxus stent(Boston Scientific Corp) </td> <td> Unselected patients (included ST-segment elevation myocardial infarction (STEMI), non-STEMI or unstable angina pectoris, and stable angina) </td> <td> follow-up <br> n=1065/1033<br> Parallel groups<br> open <br> Denmark. </td> </tr> <tr> <td> <a href="index.html"> Han, 2006 </a> <br> </td> <td> Cypher<br>  <i>versus</i> <br> Taxus </td> <td> Multivessel disease. Stable or unstable AP, no AMI </td> <td> follow-up 19.5 months (mean)<br> n=210/206<br> Parallel groups<br> open <br> China </td> </tr> <tr> <td> <a href="index.html"> BASKET (vs paclitaxel), 2005 </a> <br> </td> <td> Cypher<br>  <i>versus</i> <br> Taxus </td> <td> Unselected patients; de-novo lesions </td> <td> follow-up 6 months<br> n=264/281<br> Parallel groups<br> open <br> Switzerland, </td> </tr> <tr> <td> <a href="index.html"> ENDEAVOR II, 2006 </a> <br> </td> <td> AVE Zotarolimus-Eluting Driver<br>  <i>versus</i> <br> Driver </td> <td> single de novo native coronary artery stenosis </td> <td> follow-up 12 months<br> n=598/599<br> Parallel groups<br> double-blind <br> worldwide </td> </tr> <tr> <td> <a href="index.html"> SPIRIT I, 2005 </a> <br> NCT00180453 </td> <td> everolimus eluting sent, XIENCE<br>  <i>versus</i> <br> bare etal stent, MULTI-LINK VISION </td> <td> patients with de novo native coronary artery lesions </td> <td> follow-up 6 months (5yr)<br> n=28/32<br> Parallel groups<br> single-blind <br> </td> </tr> <tr> <td> <a href="index.html"> LEADERS, 2008 </a> <br> NCT00389220 </td> <td> BioMatrix III (biolimus-eluting stent withbiodegradable polymer)<br>  <i>versus</i> <br> Cypher SELECT (sirolimus-eluting stent with durable polymer) </td> <td> patients aged 18 years or older with chronic stable coronary artery disease or acute coronary syndromes </td> <td> follow-up 9 months<br> n=857/850<br> Parallel groups<br> open assessor-blind <br> Europe </td> </tr> <tr> <td> <a href="index.html"> SPIRIT II, 2006 </a> <br> NCT00180310 </td> <td> everolimus eluting stent, XIENCE V<br>  <i>versus</i> <br> placitaxel eluting stent, TAXUS EXPRESS2 </td> <td> De novo lesions (maximim two) </td> <td> follow-up 6 months<br> n=223/77<br> Parallel groups<br> single-blind (patient) <br> </td> </tr> <tr> <td> <a href="index.html"> ENDEAVOR III, 2006 </a> <br> NCT00217256 </td> <td> ABT-578 coated Endeavor<br>  <i>versus</i> <br> Cypher </td> <td> single de novo lesions in native coronary arteries 2.5-3.5 mm in diameter </td> <td> follow-up 12 months (and 24 months)<br> n=327/109<br> Parallel groups<br> open <br> US </td> </tr> <tr> <td> <a href="index.html"> ENDEAVOR IV, 2009 </a> <br> NCT00217269 </td> <td> zotarolimus-eluting stent (Endeavor)<br>  <i>versus</i> <br> paclitaxel-eluting stent (Taxus) </td> <td> single de novo lesions in native coronary arteries with a reference vessel diameter of 2.5-3.5 mm </td> <td> follow-up mean 36 mo<br> n=773/775<br> Parallel groups<br> open <br> US </td> </tr> <tr> <td> <a href="index.html"> SPIRIT IV, 2010 </a> <br> NCT00307047 </td> <td> XIENCE V Everolimus Eluting Coronary Stent System<br>  <i>versus</i> <br> TAXUS EXPRESS2 Paclitaxel Eluting Coronary Stent System (TAXUS). </td> <td> patients with de novo native coronary artery lesions and reference vessel diameters between 2.5 mm to 4.25 mm and lesion lengths <= 28 mm </td> <td> follow-up 1 y (2y)<br> n=2458/1229<br> Parallel groups<br> 270 days (5 years) <br> USA </td> </tr> <tr> <td> <a href="index.html"> SPIRIT III, 2008 </a> <br> NCT00180479 </td> <td> everolimus-eluting stent, XIENCE V<br>  <i>versus</i> <br> paclitaxel-eluting stent, Taxus </td> <td> lesions 28 mm or less in length and with reference vessel diameter between 2.5 and 3.75 m </td> <td> follow-up 12 months<br> n=669/333<br> Parallel groups<br> single-blind <br> US </td> </tr> <tr> <td> <a href="index.html"> ISAR-TEST-1, 2006 </a> <br> NCT00140530 </td> <td> rapamycin-eluting stent Yukon<br>  <i>versus</i> <br> Taxus </td> <td> stable or unstable anginaor a positive stress test, stable or unstable anginaor a positive stress test </td> <td> follow-up 9 months<br> n=225/225<br> Parallel groups<br> open <br> Germany </td> </tr> <tr> <td> <a href="index.html"> SORT OUT IV, 0 </a> <br> NCT00552877 </td> <td> everolimus-eluting stents<br>  <i>versus</i> <br> sirolimus-eluting stents </td> <td> unselected patients with coronary artery disease </td> <td> follow-up 9 months (3 years)<br> n=1390/1384<br> Parallel groups<br> open <br> Denmark </td> </tr> <tr> <td> <a href="index.html"> ZEST (vs SES), 2009 </a> <br> NCT00418067 </td> <td> zotarolimus-eluting stents<br>  <i>versus</i> <br> sirolimus-eluting stents </td> <td> Patients with coronary artery disease </td> <td> follow-up 1 year<br> n=883/878<br> Parallel groups<br> Open <br> Korea </td> </tr> <tr> <td> <a href="index.html"> Costar II, 2008 </a> <br> NCT00165035 </td> <td> CoStar stent (Conor MedSystems) PES<br>  <i>versus</i> <br> Taxus (Boston Scientific) PES </td> <td> patient undergoing percutaneous coronary intervention for a single lesion per vessel in up to three native epicardial vessels </td> <td> follow-up 8 months (1 year)<br> n=989/686<br> Parallel groups<br> single-blind <br> US, Germany, Belgium, and New Zealand </td> </tr> <tr> <td> <a href="index.html"> Wessely, 2008 </a> <br> </td> <td> rapamycin polymer-coated drug-eluting stent<br>  <i>versus</i> <br> paclitaxel polymer-coated drug-eluting stent </td> <td> </td> <td> follow-up 9 months<br> n=-9/-9<br> Parallel groups<br> NA <br> Germany </td> </tr> <tr> <td> <a href="index.html"> ZEST (vs PES), 2009 </a> <br> NCT00418067 </td> <td> zotarolimus-eluting stents<br>  <i>versus</i> <br> paclitaxel-eluting stents </td> <td> Patients with coronary artery disease </td> <td> follow-up 1 year<br> n=883/884<br> <br> NA <br> </td> </tr> <tr> <td> <a href="index.html"> ISAR-TEST-4 (biodegradable polymer), 2009 </a> <br> NCT00598676). </td> <td> biodegradable polymer rapamycin-eluting stent<br>  <i>versus</i> <br> permanent polymer-based rapamycin-eluting or everolimus-eluting </td> <td> patients with stable coronary disease or acute coronary syndromes with de novo native-vessel stent implantation </td> <td> follow-up 12 mo<br> n=1299/1304<br> Parallel groups<br> open <br> Germany </td> </tr> <tr> <td> <a href="index.html"> COMPARE, 2009 </a> <br> NCT01016041 </td> <td> polymer based, everolimus-eluting stent (Xience V)<br>  <i>versus</i> <br> polymer-based, paclitaxel-eluting stent (Taxus Liberte) </td> <td> unselected patients </td> <td> follow-up 1 y (2y)<br> n=897/903<br> Parallel groups<br> open <br> the Netherlands </td> </tr> <tr> <td> <a href="index.html"> RESOLUTE All comers, 2010 </a> <br> NCT00617084.) </td> <td> zotarolimus-eluting stent<br>  <i>versus</i> <br> everolimus-eluting stent (Xience) </td> <td> adult patients with chronic, stable coronary artery disease or acute coronary syndromes, including myocardial infarction with or without ST-segment elevation </td> <td> follow-up 12 months (5y)<br> n=1140/1152<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="index.html"> PERSEUS Workhorse, 2010 </a> <br> NCT00484315 </td> <td> platinum-chromium alloy, paclitaxel-eluting stent TAXUS Element<br>  <i>versus</i> <br> paclitaxel-eluting stent TAXUS Express 2 </td> <td> De Novo Coronary Artery Lesions; stent patients with lesions <28 mm in length in coronary vessels between 2.75 mm and 4.0 mm in diameter </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> FRE-RACE, 0 </a> <br> NCT00130546 </td> <td> Cypher select<br>  <i>versus</i> <br> Taxus </td> <td> de novo native coronary lesions with two or more coronary artery stenoses </td> <td> follow-up <br> n=-9/-9<br> Cross over<br> <br> </td> </tr> <tr> <td> <a href="index.html"> ZoMaxx phase 2, 0 </a> <br> NCT00140101 </td> <td> ZoMaxx drug-eluting stent<br>  <i>versus</i> <br> TAXUS Express2 </td> <td> de Novo Coronary Artery Lesions </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> PROTECT, 0 </a> <br> NCT00476957 </td> <td> Medtronic Endeavor Zotarolimus Eluting Coronary Stent System<br>  <i>versus</i> <br> Cordis Cypher Sirolimus-eluting Coronary Stent </td> <td> unselected patients </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> MIDCAB Versus DES in Proximal LAD Lesions, 0 </a> <br> NCT00299429 </td> <td> sirolimus-coated stent<br>  <i>versus</i> <br> minimally invasive bypass surgery </td> <td> patients with isolated proximal left anterior descending coronary arteries </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> FEMH-93005, 0 </a> <br> NCT00190099 </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> GENESIS Trial CP-01, 0 </a> <br> NCT00322569 </td> <td> Corio Pimecrolimus<br>  <i>versus</i> <br> CoStar </td> <td> patients with de novo lesions of the native coronary arteries </td> <td> follow-up 6 months<br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> TRIAS-Low-Risk , 0 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> COMBAT, 0 </a> <br> </td> <td> PCI<br>  <i>versus</i> <br> CABG </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Korean Randomized Study, 0 </a> <br> </td> <td> PCI<br>  <i>versus</i> <br> CABG </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Munich Study, 0 </a> <br> </td> <td> sirolimus<br>  <i>versus</i> <br> CABG </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> REVASCULARIZE, 0 </a> <br> </td> <td> PCI<br>  <i>versus</i> <br> CABG </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> BASKET-PROVE, 2008 </a> <br> </td> <td> Cypher<br>  <i>versus</i> <br> Vision </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Gao, </a> <br> NCT00887211 </td> <td> ProStent rapamycin-eluting stent system<br>  <i>versus</i> <br> Firebird drug-eluting stents </td> <td> </td> <td> follow-up <br> n=-9/-9<br> Parallel groups<br> single blind <br> </td> </tr> </table> <h2>References</h2> <p> <b>Kochiadakis, 2007 : </b> Kochiadakis GE, Marketou ME, Arfanakis DA, Sfiridaki K, Skalidis EI, Igoumenidis NE, Hamilos MI, Kolyvaki S, Chlouverakis G, Kantidaki E, Castanas E, Vardas PE, Reduced systemic inflammatory response to implantation of sirolimus-eluting stents in patients with stable coronary artery disease. <i>Atherosclerosis 2007;194:433-8.</i> [PMID 16997310] 10.1016/j.atherosclerosis.2006.08.029 </p> <p> <b>RAVEL, 2002 : </b> Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnr F, Falotico RA randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. <i>N Engl J Med 2002;346:1773-80</i> [PMID 12050336] </p> <p> <b>RAVEL, 2002 : </b> Morice MC, Serruys PW, Barragan P, Bode C, Van Es GA, Stoll HP, Snead D, Mauri L, Cutlip DE, Sousa ELong-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial. <i>J Am Coll Cardiol 2007 Oct 2;50:1299-304</i> [PMID 17903626] </p> <p> <b>SIRIUS, 2003 : </b> Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RESirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. <i>N Engl J Med 2003;349:1315-23</i> [PMID 14523139] </p> <p> <b>SIRIUS, 2003 : </b> Weisz G, Moses JW, Teirstein PS, Holmes DR Jr, Raizner AE, Satler LF, Mishkel G, Wilensky RL, Wang P, Kuntz RE, Popma JJ, Leon MBSafety of sirolimus-eluting stenting and its effect on restenosis in patients with unstable angina pectoris (a SIRIUS substudy). <i>Am J Cardiol 2007 Apr 15;99:1044-50</i> [PMID 17437725] </p> <p> <b>SIRIUS, 2003 : </b> Holmes DR Jr, Leon MB, Moses JW, Popma JJ, Cutlip D, Fitzgerald PJ, Brown C, Fischell T, Wong SC, Midei M, Snead D, Kuntz REAnalysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. <i>Circulation 2004;109:634-40</i> [PMID 14769686] </p> <p> <b>SIRIUS, 2003 : </b> Weisz G, Leon MB, Holmes DR Jr, Kereiakes DJ, Popma JJ, Teirstein PS, Cohen SA, Wang H, Cutlip DE, Moses JWFive-year follow-up after sirolimus-eluting stent implantation results of the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) Trial. <i>J Am Coll Cardiol 2009 Apr 28;53:1488-97</i> [PMID 19389558] 10.1016/j.jacc.2009.01.050 </p> <p> <b>SIRIUS, 2003 : </b> Novack V, Nguyen MC, Rooney M, Chacko R, Novack L, Pencina M, Apruzzese P, Mauri L, Cohen SA, Moses J, Leon MB, Cutlip DEEffect of coronary target lesion revascularization on late cardiac events after insertion of sirolimus-eluting or bare metal stents. <i>Am J Cardiol 2010 Sep 15;106:774-9</i> [PMID 20816116] 10.1016/j.amjcard.2010.04.039 </p> <p> <b>C-SIRIUS, 2004 : </b> Schampaert E, Cohen EA, Schlter M, Reeves F, Traboulsi M, Title LM, Kuntz RE, Popma JJThe Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). <i>J Am Coll Cardiol 2004;43:1110-5</i> [PMID 15028375] </p> <p> <b>E-SIRIUS, 2003 : </b> Schofer J, Schlter M, Gershlick AH, Wijns W, Garcia E, Schampaert E, Breithardt GSirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). <i>Lancet 2003;362:1093-9</i> [PMID 14550694] </p> <p> <b>TAXUS I, 2003 : </b> Grube E, Silber S, Hauptmann KE, Mueller R, Buellesfeld L, Gerckens U, Russell METAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. <i>Circulation 2003;107:38-42</i> [PMID 12515740] </p> <p> <b>TAXUS I, 2003 : </b> Grube E, Silber S, Hauptmann KE, Mueller R, Buellesfeld L, Gerckens U, Russell METAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. <i>Circulation 2003 Jan 7;107:38-42</i> [PMID 12515740] </p> <p> <b>TAXUS II, 2003 : </b> Colombo A, Drzewiecki J, Banning A, Grube E, Hauptmann K, Silber S, Dudek D, Fort S, Schiele F, Zmudka K, Guagliumi G, Russell MERandomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. <i>Circulation 2003;108:788-94</i> [PMID 12900339] </p> <p> <b>TAXUS II, 2003 : </b> Silber S, Colombo A, Banning AP, Hauptmann K, Drzewiecki J, Grube E, Dudek D, Baim DSFinal 5-year results of the TAXUS II trial: a randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for de novo coronary artery lesions. <i>Circulation 2009 Oct 13;120:1498-504</i> [PMID 19786634] </p> <p> <b>TAXUS IV, 2004 : </b> Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell MEA polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. <i>N Engl J Med 2004;350:221-31</i> [PMID 14724301] </p> <p> <b>TAXUS IV, 2004 : </b> Ellis SG, Stone GW, Cox DA, Hermiller J, O'Shaughnessy C, Mann T, Turco M, Caputo R, Bergin PJ, Bowman TS, Baim DSLong-Term Safety and Efficacy With Paclitaxel-Eluting Stents 5-Year Final Results of the TAXUS IV Clinical Trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent). <i>JACC Cardiovasc Interv 2009 Dec;2:1248-59</i> [PMID 20129552] 10.1016/j.jcin.2009.10.003 </p> <p> <b>TAXUS IV, 2004 : </b> Ellis SG, Stone GW, Cox DA, Hermiller J, O'Shaughnessy C, Mann T, Turco M, Caputo R, Bergin PJ, Bowman TS, Baim DSLong-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent). <i>JACC Cardiovasc Interv 2009;2:1248-59</i> [PMID 20129552] 10.1016/j.jcin.2009.10.003 </p> <p> <b>ASPECT, 2003 : </b> Park SJ, Shim WH, Ho DS, Raizner AE, Park SW, Hong MK, Lee CW, Choi D, Jang Y, Lam R, Weissman NJ, Mintz GSA paclitaxel-eluting stent for the prevention of coronary restenosis. <i>N Engl J Med 2003;348:1537-45</i> [PMID 12700373] </p> <p> <b>ELUTES, 2004 : </b> Gershlick A, De Scheerder I, Chevalier B, Stephens-Lloyd A, Camenzind E, Vrints C, Reifart N, Missault L, Goy JJ, Brinker JA, Raizner AE, Urban P, Heldman AWInhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent: the European evaLUation of pacliTaxel Eluting Stent (ELUTES) trial. <i>Circulation 2004;109:487-93</i> [PMID 14744971] </p> <p> <b>DELIVER, 2004 : </b> ONeill WW, Knopf W, Lansky A, Fitzgerald P, Mahaffey K.Randomized comparison of paclitaxel-coated versus metallic stentsfor treatment of coronary lesions <i>American College of CardiologyScientific Session, March, 2003</i> [PMID ] </p> <p> <b>DELIVER, 2004 : </b> Knopf W, ONeill WW, Lansky A, Fitzgerald P, Mahaffey KERandomized comparison of paclitaxel-coated versus metallicstents for treatment of coronary lesions <i>TranscatheterCardiovascular Therapeutics Annual Meeting, September, 2003</i> [PMID ] </p> <p> <b>DELIVER, 2004 : </b> Lansky AJ, Costa RA, Mintz GS, Tsuchiya Y, Midei M, Cox DA, O'Shaughnessy C, Applegate RA, Cannon LA, Mooney M, Farah A, Tannenbaum MA, Yakubov S, Kereiakes DJ, Wong SC, Kaplan B, Cristea E, Stone GW, Leon MB, Knopf WD, O'Neill WWNon-polymer-based paclitaxel-coated coronary stents for the treatment of patients with de novo coronary lesions: angiographic follow-up of the DELIVER clinical trial. <i>Circulation 2004 Apr 27;109:1948-54</i> [PMID 15078794] </p> <p> <b>PATENCY, 2002 : </b> Heldman A, Farhat N, Fry E, et al.bPaclitaxel-eluting stent for cytostatic prevention of restenosis: the PATENCY Study <i>Transcatheter Cardiovascular Therapeutics Annual Meeting,September, 2002</i> [PMID ] </p> <p> <b>SCORE, 2004 : </b> Stone GW.Adverse outcomes from a taxane-loaded polymericsleeved stent: final results from the SCORE Tria <i>AmericanCollege of Cardiology Scientific Session, March, 2002</i> [PMID ] </p> <p> <b>SCORE, 2004 : </b> Grube E, Lansky A, Hauptmann KE, Di Mario C, Di Sciascio G, Colombo A, Silber S, Stumpf J, Reifart N, Fajadet J, Marzocchi A, Schofer J, Dumas P, Hoffmann R, Guagliumi G, Pitney M, Russell MEHigh-dose 7-hexanoyltaxol-eluting stent with polymer sleeves for coronary revascularization: one-year results from the SCORE randomized trial. <i>J Am Coll Cardiol 2004 Oct 6;44:1368-72</i> [PMID 15464315] </p> <p> <b>ACTION, 2004 : </b> Serruys PW, Veldhof S, Stuteville M, et alActinomycin-elutingstent improves outcome by reducing neointimal hyperplasia <i>Transcatheter Cardiovascular Therapeutics Annual Meeting,September, 2002</i> [PMID ] </p> <p> <b>ACTION, 2004 : </b> Serruys PW, Ormiston JA, Sianos G, Sousa JE, Grube E, den Heijer P, de Feyter P, Buszman P, Schmig A, Marco J, Polonski L, Thuesen L, Zeiher AM, Bett JH, Suttorp MJ, Glogar HD, Pitney M, Wilkins GT, Whitbourn R, Veldhof S, Miquel K, Johnson R, Coleman L,Actinomycin-eluting stent for coronary revascularization: a randomized feasibility and safety study: the ACTION trial. <i>J Am Coll Cardiol 2004 Oct 6;44:1363-7</i> [PMID 15464314] </p> <p> <b>FUTURE I, 2004 : </b> Grube E, Sonoda S, Ikeno F, Honda Y, Kar S, Chan C, Gerckens U, Lansky AJ, Fitzgerald PJSix- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer. <i>Circulation 2004;109:2168-71</i> [PMID 15123533] </p> <p> <b>FUTURE II, 2006 : </b> Grube E, Lansky A, Mehran R, Fitzgerald P, HoMulticenter evaluation of the bioabsorbable polymer-basedeverolimus-eluting stent: FUTURE-2 trial <i>TranscatheterCardiovascular Therapeutic Annual Meeting, September, 2003</i> [PMID ] </p> <p> <b>FUTURE II, 2006 : </b> Tsuchiya Y, Lansky AJ, Costa RA, Mehran R, Pietras C, Shimada Y, Sonoda S, Cristea E, Negoita M, Dangas GD, Moses JW, Leon MB, Fitzgerald PJ, Mller R, Strger H, Hauptmann KE, Grube EEffect of everolimus-eluting stents in different vessel sizes (from the pooled FUTURE I and II trials). <i>Am J Cardiol 2006 Aug 15;98:464-9</i> [PMID 16893698] </p> <p> <b>FUTURE II, 2006 : </b> Grube E, Sonoda S, Ikeno F, Honda Y, Kar S, Chan C, Gerckens U, Lansky AJ, Fitzgerald PJSix- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer. <i>Circulation 2004 May 11;109:2168-71</i> [PMID 15123533] </p> <p> <b>Pache et al, 2005 : </b> Pache J, Dibra A, Mehilli J, Dirschinger J, Schmig A, Kastrati ADrug-eluting stents compared with thin-strut bare stents for the reduction of restenosis: a prospective, randomized trial. <i>Eur Heart J 2005;26:1262-8</i> [PMID 15737962] </p> <p> <b>Ortolani et al, 2007 : </b> Ortolani P, Marzocchi A, Marrozzini C, Palmerini T, Saia F, Taglieri N, Aquilina M, Baldazzi F, Silenzi S, Cooke RM, Reggiani ML, Branzi ARandomized comparative trial of a thin-strut bare metal cobalt-chromium stent versus a sirolimus-eluting stent for coronary revascularization. <i>Catheter Cardiovasc Interv 2007;69:790-8</i> [PMID 17290437] </p> <p> <b>TAXi, 2005 : </b> Goy JJ, Stauffer JC, Siegenthaler M, Benot A, Seydoux CA prospective randomized comparison between paclitaxel and sirolimus stents in the real world of interventional cardiology: the TAXi trial. <i>J Am Coll Cardiol 2005;45:308-11</i> [PMID 15653032] </p> <p> <b>TAXi, 2005 : </b> Berger A, Stauffer JC, Seydoux C, Siegenthaler M, Benot A, Goy JJThree-year follow-up of the first prospective randomized comparison between paclitaxel and sirolimus stents: the TAXi-LATE trial. <i>Catheter Cardiovasc Interv 2007 Aug 1;70:163-6</i> [PMID 17630653] </p> <p> <b>SIRTAX (Windecker), 2005 : </b> Windecker S, Remondino A, Eberli FR, Jni P, Rber L, Wenaweser P, Togni M, Billinger M, Tller D, Seiler C, Roffi M, Corti R, Stsch G, Maier W, Lscher T, Hess OM, Egger M, Meier BSirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. <i>N Engl J Med 2005;353:653-62</i> [PMID 16105989] </p> <p> <b>REALITY, 2006 : </b> Morice MC, Colombo A, Meier B, Serruys P, Tamburino C, Guagliumi G, Sousa E, Stoll HPSirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial. <i>JAMA 2006;295:895-904</i> [PMID 16493102] </p> <p> <b>Zhang (SES vs PES), 2006 : </b> Zhang Q, Zhang RY, Zhang JS, Hu J, Yang ZK, Ni J, Fang YH, Zhang X, Shen WFOne-year clinical outcomes of Chinese sirolimus-eluting stent in the treatment of unselected patients with coronary artery disease. <i>Chin Med J (Engl) 2006;119:165-8</i> [PMID 16455001] </p> <p> <b>SORT OUT II, 2008 : </b> Galloe AM.prospective multi-center, large-scale, randomized trialof paclitaxel- and sirolimus-eluting stents in real-world lesions <i>Annual Scientifi c Meeting of the Transcatheter CardiovascularTherapeutics; Washington, DC; Oct 2227, 2006</i> [PMID ] </p> <p> <b>SORT OUT II, 2008 : </b> Galle AM, Thuesen L, Kelbaek H, Thayssen P, Rasmussen K, Hansen PR, Bligaard N, Saunamki K, Junker A, Aare J, Abildgaard U, Ravkilde J, Engstrm T, Jensen JS, Andersen HR, Btker HE, Galatius S, Kristensen SD, Madsen JK, Krusell LR, Abildstrm SZ, StepComparison of paclitaxel- and sirolimus-eluting stents in everyday clinical practice: the SORT OUT II randomized trial. <i>JAMA 2008;299:409-16</i> [PMID 18230778] </p> <p> <b>Han, 2006 : </b> Han YL, Wang XZ, Jing QM, Wang SL, Ma YY, Luan B[Comparison of Rapamycin and Paclitaxel eluting stent in patients with multi-vessel coronary disease] <i>Zhonghua Xin Xue Guan Bing Za Zhi 2006;34:123-6</i> [PMID 16626577] </p> <p> <b>BASKET (vs paclitaxel), 2005 : </b> Kaiser C, Brunner-La Rocca HP, Buser PT, Bonetti PO, Osswald S, Linka A, Bernheim A, Zutter A, Zellweger M, Grize L, Pfisterer MEIncremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitts Trial (BASKET). <i>Lancet 2005;366:921-9</i> [PMID 16154019] </p> <p> <b>Stone pooled analysis sirolimus, 2007 : </b> Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, Colombo A, Schampaert E, Grube E, Kirtane AJ, Cutlip DE, Fahy M, Pocock SJ, Mehran R, Leon MBSafety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. <i>N Engl J Med 2007;356:998-1008</i> [PMID 17296824] </p> <p> <b>Stone pooled analysis TAXUS studies, 2007 : </b> Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, Colombo A, Schampaert E, Grube E, Kirtane AJ, Cutlip DE, Fahy M, Pocock SJ, Mehran R, Leon MBSafety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. <i>N Engl J Med 2007;356:998-1008</i> [PMID 17296824] </p> <p> <b>Spaulding pooled analysis Ravel Sirius studies, 2007 : </b> Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PWA pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. <i>N Engl J Med 2007;356:989-97</i> [PMID 17296825] </p> <p> <b>ENDEAVOR II, 2006 : </b> Gruberg L.ENDEAVOR II. A randomized comparison of the Endeavor ABT-578 drug-eluting stent with a bare metal stent for coronary revascularization,powerpo <i>http://www.medscape.com/viewarticle/501475</i> [PMID ] </p> <p> <b>ENDEAVOR II, 2006 : </b> Fajadet J, Wijns W, Laarman GJ, Kuck KH, Ormiston J, Mnzel T, Popma JJ, Fitzgerald PJ, Bonan R, Kuntz RERandomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. <i>Circulation 2006 Aug 22;114:798-806</i> [PMID 16908773] </p> <p> <b>ENDEAVOR II, 2006 : </b> Fajadet J, Wijns W, Laarman GJ, Kuck KH, Ormiston J, Mnzel T, Popma JJ, Fitzgerald PJ, Bonan R, Kuntz RERandomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions. Clinical and angiographic results of the ENDEAVOR II Trial. <i>Minerva Cardioangiol 2007 Feb;55:1-18</i> [PMID 17287679] </p> <p> <b>ENDEAVOR II, 2006 : </b> Sakurai R, Hongo Y, Yamasaki M, Honda Y, Bonneau HN, Yock PG, Cutlip D, Popma JJ, Zimetbaum P, Fajadet J, Kuntz RE, Wijns W, Fitzgerald PJDetailed intravascular ultrasound analysis of Zotarolimus-eluting phosphorylcholine-coated cobalt-chromium alloy stent in de novo coronary lesions (results from the ENDEAVOR II trial). <i>Am J Cardiol 2007 Sep 1;100:818-23</i> [PMID 17719326] </p> <p> <b>ENDEAVOR II, 2006 : </b> Eisenstein EL, Wijns W, Fajadet J, Mauri L, Edwards R, Cowper PA, Kong DF, Anstrom KJLong-Term Clinical and Economic Analysis of the Endeavor Drug-Eluting Stent Versus the Driver Bare-Metal Stent 4-Year Results From the ENDEAVOR II Trial (Randomized Controlled Trial to Evaluate the Safety and Efficacy of the Medtronic AVE ABT-578 Eluting Driver Coronary Stent in De Novo Native Coronary Artery Lesions). <i>JACC Cardiovasc Interv 2009 Dec;2:1178-87</i> [PMID 20129543] 10.1016/j.jcin.2009.10.011 </p> <p> <b>ABSORB, 0 : </b> Ormiston JA, Serruys PW, Regar E, Dudek D, Thuesen L, Webster MW, Onuma Y, Garcia-Garcia HM, McGreevy R, Veldhof SA bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. <i>Lancet 2008 Mar 15;371:899-907</i> [PMID 18342684] </p> <p> <b>pooled SIRIUS (diabetics), 0 : </b> Schampaert E.Sirolimus-eluting stents in diabetics: SIRIUS, C-SIRIUSand E-SIRIUS <i>TCT</i> [PMID ] </p> <p> <b>SPIRIT I, 2005 : </b> Serruys PW, Ong AT, Piek JJ, Neumann FJ, van der Giessen WJ, Wiemer M, Zeiher A, Grube E, Haase J, Thuesen L, Hamm C, Otto-Terlouw PCA randomized comparison of a durable polymer Everolimus-eluting stent with a bare metal coronary stent: The SPIRIT first trial. <i>EuroIntervention 2005 May;1:58-65</i> [PMID 19758878] </p> <p> <b>SPIRIT I, 2005 : </b> Tsuchida K, Piek JJ, Neumann FJ, van der Giessen WJ, Wiemer M, Zeiher AM, Grube E, Haase J, Thuesen L, Hamm CW, Veldhof S, Dorange C, Serruys PWOne-year results of a durable polymer everolimus-eluting stent in de novo coronary narrowings (The SPIRIT FIRST Trial). <i>EuroIntervention 2005 Nov;1:266-72</i> [PMID 19758915] </p> <p> <b>SPIRIT I, 2005 : </b> Tsuchida K, Garca-Garca HM, Ong AT, Valgimigli M, Aoki J, Rademaker TA, Morel MA, van Es GA, Bruining N, Serruys PWRevisiting late loss and neointimal volumetric measurements in a drug-eluting stent trial: analysis from the SPIRIT FIRST trial. <i>Catheter Cardiovasc Interv 2006 Feb;67:188-97</i> [PMID 16400664] </p> <p> <b>PERSEUS Workhorse, 2010 : </b> Allocco DJ, Cannon LA, Britt A, Heil JE, Nersesov A, Wehrenberg S, Dawkins KD, Kereiakes DJA prospective evaluation of the safety and efficacy of the TAXUS Element paclitaxel-eluting coronary stent system for the treatment of de novo coronary artery lesions: design and statistical methods of the PERSEUS clinical program. <i>Trials 2010 Jan 7;11:1</i> [PMID 20059766] </p> <p> <b>PERSEUS Workhorse, 2010 : </b> Weber MA, Bakris GL, Jamerson K, Weir M, Kjeldsen SE, Devereux RB, Velazquez EJ, Dahlöf B, Kelly RY, Hua TA, Hester A, Pitt BCardiovascular events during differing hypertension therapies in patients with diabetes. <i>J Am Coll Cardiol 2010;56:77-85</i> [PMID 20620720] 10.1016/j.jacc.2010.02.046 </p> <p> <b>LEADERS, 2008 : </b> Windecker S, Serruys PW, Wandel S, Buszman P, Trznadel S, Linke A, Lenk K, Ischinger T, Klauss V, Eberli F, Corti R, Wijns W, Morice MC, di Mario C, Davies S, van Geuns RJ, Eerdmans P, van Es GA, Meier B, Jni PBiolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. <i>Lancet 2008 Aug 31;:</i> [PMID 18765162] </p> <p> <b>SPIRIT II, 2006 : </b> Garg S, Serruys P, Onuma Y, Dorange C, Veldhof S, Miquel-Hébert K, Sudhir K, Boland J, Huber K, Garcia E, Te Riele JA3-Year Clinical Follow-Up of the XIENCE V Everolimus-Eluting Coronary Stent System in the Treatment of Patients With De Novo Coronary Artery Lesions The SPIRIT II Trial (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions). <i>JACC Cardiovasc Interv 2009 Dec;2:1190-8</i> [PMID 20129545] 10.1016/j.jcin.2009.10.002 </p> <p> <b>SPIRIT II, 2006 : </b> Onuma Y, Tanimoto S, Ruygrok P, Neuzner J, Piek JJ, Seth A, Schofer JJ, Richardt G, Wiemer M, Carrié D, Thuesen L, Dorange C, Miquel-Hebert K, Veldhof S, Serruys PWEfficacy of everolimus eluting stent implantation in patients with calcified coronary culprit lesions: two-year angiographic and three-year clinical results from the SPIRIT II study. <i>Catheter Cardiovasc Interv 2010;76:634-42</i> [PMID 20690152] 10.1002/ccd.22541 </p> <p> <b>ENDEAVOR III, 2006 : </b> Miyazawa A, Ako J, Hongo Y, Hur SH, Tsujino I, Courtney BK, Hassan AH, Kandzari DE, Honda Y, Fitzgerald PJ, , Comparison of vascular response to zotarolimus-eluting stent versus sirolimus-eluting stent: intravascular ultrasound results from ENDEAVOR III. <i>Am Heart J 2008;155:108-13.</i> [PMID 18082499] 10.1016/j.ahj.2007.08.008 </p> <p> <b>ENDEAVOR III, 2006 : </b> Kandzari DE, Leon MB, Popma JJ, Fitzgerald PJ, O'Shaughnessy C, Ball MW, Turco M, Applegate RJ, Gurbel PA, Midei MG, Badre SS, Mauri L, Thompson KP, LeNarz LA, Kuntz REComparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. <i>J Am Coll Cardiol 2006;48:2440-7</i> [PMID 17174180] </p> <p> <b>ENDEAVOR III, 2006 : </b> Eisenstein EL, Leon MB, Kandzari DE, Mauri L, Edwards R, Kong DF, Cowper PA, Anstrom KJLong-Term Clinical and Economic Analysis of the Endeavor Zotarolimus-Eluting Stent Versus the Cypher Sirolimus-Eluting Stent 3-Year Results From the ENDEAVOR III Trial (Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions). <i>JACC Cardiovasc Interv 2009 Dec;2:1199-207</i> [PMID 20129546] 10.1016/j.jcin.2009.10.009 </p> <p> <b>ENDEAVOR IV, 2009 : </b> Leon MBEndeavor Clinical Program Overview, <i> FDA Advisory Panel, October 10th, 2007</i> [PMID ] </p> <p> <b>ENDEAVOR IV, 2009 : </b> Waseda K, Miyazawa A, Ako J, Hasegawa T, Tsujino I, Sakurai R, Yock PG, Honda Y, Kandzari DE, Leon MB, Fitzgerald PJIntravascular ultrasound results from the ENDEAVOR IV trial: randomized comparison between zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease. <i>JACC Cardiovasc Interv 2009 Aug;2:779-84</i> [PMID 19695548] </p> <p> <b>ENDEAVOR IV, 2009 : </b> Leon MB, Kandzari DE, Eisenstein EL, Anstrom KJ, Mauri L, Cutlip DE, Nikolsky E, O'Shaughnessy C, Overlie PA, Kirtane AJ, McLaurin BT, Solomon SL, Douglas JS Jr, Popma JJLate Safety, Efficacy, and Cost-Effectiveness of a Zotarolimus-Eluting Stent Compared With a Paclitaxel-Eluting Stent in Patients With De Novo Coronary Lesions 2-Year Follow-Up From the ENDEAVOR IV Trial (Randomized, Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions). <i>JACC Cardiovasc Interv 2009 Dec;2:1208-18</i> [PMID 20129547] 10.1016/j.jcin.2009.10.008 </p> <p> <b>ENDEAVOR IV, 2009 : </b> Leon MB, Nikolsky E, Cutlip DE, Mauri L, Liberman H, Wilson H, Patterson J, Moses J, Kandzari DEImproved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial. <i>JACC Cardiovasc Interv 2010;3:1043-50</i> [PMID 20965463] 10.1016/j.jcin.2010.07.008 </p> <p> <b>SPIRIT IV, 2010 : </b> Nikolsky E, Lansky AJ, Sudhir K, Doostzadeh J, Cutlip DE, Piana R, Su X, White R, Simonton CA, Stone GWSPIRIT IV trial design: a large-scale randomized comparison of everolimus-eluting stents and paclitaxel-eluting stents in patients with coronary artery disease. <i>Am Heart J 2009;158:520-526.e2</i> [PMID 19781409] </p> <p> <b>SPIRIT IV, 2010 : </b> Stone GW, Rizvi A, Newman W, Mastali K, Wang JC, Caputo R, Doostzadeh J, Cao S, Simonton CA, Sudhir K, Lansky AJ, Cutlip DE, Kereiakes DJEverolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. <i>N Engl J Med 2010 May 6;362:1663-74</i> [PMID 20445180] 10.1056/NEJMoa0910496 </p> <p> <b>SPIRIT IV, 2010 : </b> Kereiakes DJ, Cutlip DE, Applegate RJ, Wang J, Yaqub M, Sood P, Su X, Su G, Farhat N, Rizvi A, Simonton CA, Sudhir K, Stone GWOutcomes in diabetic and nondiabetic patients treated with everolimus- or paclitaxel-eluting stents: results from the SPIRIT IV clinical trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System). <i>J Am Coll Cardiol 2010;56:2084-9</i> [PMID 21144968] 10.1016/j.jacc.2010.10.006 </p> <p> <b>SPIRIT III, 2008 : </b> Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, Farhat N, Mahaffey KW, Cutlip DE, Fitzgerald PJ, Sood P, Su X, Lansky AJ, , Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. <i>JAMA 2008;299:1903-13.</i> [PMID 18430909] 10.1001/jama.299.16.1903 </p> <p> <b>SPIRIT III, 2008 : </b> Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, Farhat N, Caputo R, Xenopoulos N, Applegate R, Gordon P, White RM, Sudhir K, Cutlip DE, Petersen JL <i>Circulation 2009;119:680-6</i> [PMID 19171853] </p> <p> <b>SPIRIT III, 2008 : </b> Applegate RJ, Hermiller JJ, Sanz M, Doostzadeh J, Pierson W, Su X, Lansky AJ, Sudhir K, Stone GWComparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients with two treated vessels: 2-year results from the SPIRIT III randomised trial. <i>EuroIntervention 2010;6:437-46</i> [PMID 20884430] 10.4244/EIJ30V6I4A75 </p> <p> <b>ISAR-TEST-1, 2006 : </b> Mehilli J, Kastrati A, Wessely R, Dibra A, Hausleiter J, Jaschke B, Dirschinger J, Schmig ARandomized trial of a nonpolymer-based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss. <i>Circulation 2006;113:273-9</i> [PMID 16391155] </p> <p> <b>ZoMaxx phase 3, 2007 : </b> Abizaid A, Lansky AJ, Fitzgerald PJ, Tanajura LF, Feres F, Staico R, Mattos L, Abizaid A, Chaves A, Centemero M, Sousa AG, Sousa JE, Zaugg MJ, Schwartz LBPercutaneous coronary revascularization using a trilayer metal phosphorylcholine-coated zotarolimus-eluting stent. <i>Am J Cardiol 2007 May 15;99:1403-8</i> [PMID 17493469] </p> <p> <b>RESEARCH à effacer, 2004 : </b> Lemos PA, Hoye A, Goedhart D, Arampatzis CA, Saia F, van der Giessen WJ, McFadden E, Sianos G, Smits PC, Hofma SH, de Feyter PJ, van Domburg RT, Serruys PWClinical, angiographic, and procedural predictors of angiographic restenosis after sirolimus-eluting stent implantation in complex patients: an evaluation from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) study. <i>Circulation 2004;109:1366-70</i> [PMID 14993127] </p> <p> <b>ZEST (vs SES), 2009 : </b> Park DW, Kim YH, Yun SC, Kang SJ, Lee SW, Lee CW, Park SW, Seong IW, Lee JH, Tahk SJ, Jeong MH, Jang Y, Cheong SS, Yang JY, Lim DS, Seung KB, Chae JK, Hur SH, Lee SG, Yoon J, Lee NH, Choi YJ, Kim HS, Kim KS, Kim HS, Hong TJ, Park HS, Park SJComparison of Zotarolimus-Eluting Stents With Sirolimus- and Paclitaxel-Eluting Stents for Coronary Revascularization The ZEST (Comparison of the Efficacy and Safety of Zotarolimus-Eluting Stent with Sirolimus-Eluting and PacliTaxel-Eluting Stent for Coronary Lesions) Randomized Trial. <i>J Am Coll Cardiol 2010 Oct 5;56:1187-95</i> [PMID 20883925] 10.1016/j.jacc.2010.03.086 </p> <p> <b>ISAR, 2005 : </b> Hausleiter J, Kastrati A, Wessely R, Dibra A, Mehilli J, Schratzenstaller T, Graf I, Renke-Gluszko M, Behnisch B, Dirschinger J, Wintermantel E, Schmig APrevention of restenosis by a novel drug-eluting stent system with a dose-adjustable, polymer-free, on-site stent coating. <i>Eur Heart J 2005;26:1475-81</i> [PMID 15975990] </p> <p> <b>Costar II, 2008 : </b> Krucoff MW, Kereiakes DJ, Petersen JL, Mehran R, Hasselblad V, Lansky AJ, Fitzgerald PJ, Garg J, Turco MA, Simonton CA 3rd, Verheye S, Dubois CL, Gammon R, Batchelor WB, O'Shaughnessy CD, Hermiller JB Jr, Schofer J, Buchbinder M, Wijns WA novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study. <i>J Am Coll Cardiol 2008 Apr 22;51:1543-52</i> [PMID 18420096] </p> <p> <b>Costar II, 2008 : </b> Kereiakes DJ, Petersen JL, Batchelor WB, Fitzgerald PJ, Mehran R, Lansky A, Tsujino I, Schofer J, Dubois C, Verheye S, Cristea E, Garg J, Wijns W, Krucoff MWClinical and angiographic outcomes in diabetic patients following single or multivessel stenting in the COSTAR II randomized trial. <i>J Invasive Cardiol 2008;20:335-41</i> [PMID 18599890] </p> <p> <b>Wessely, 2008 : </b> Wessely R, Kastrati A, Mehilli J, Dibra A, Pache J, Schmig ARandomized trial of rapamycin- and paclitaxel-eluting stents with identical biodegradable polymeric coating and design. <i>Eur Heart J 2007 Nov;28:2720-5</i> [PMID 17921531] </p> <p> <b>BASKET-PROVE, 2008 : </b> Pfisterer M, Bertel O, Bonetti PO, Brunner-La Rocca HP, Eberli FR, Erne P, Galatius S, Hornig B, Kiowski W, Pachinger O, Pedrazzini G, Rickli H, De Servi S, Kaiser C, , Drug-eluting or bare-metal stents for large coronary vessel stenting? The BASKET-PROVE (PROspective Validation Examination) trial: study protocol and design. <i>Am Heart J 2008;155:609-14.</i> [PMID 18371466] 10.1016/j.ahj.2007.11.011 </p> <p> <b>ZEST (vs PES), 2009 : </b> Seung-Jung Park Comparison of Sirolimus and Paclitaxel-Eluting Stents Versus Zotarolimus-Eluting Stents in Real World Practice: The ZEST Randomized Controlled Trial <i>ACC.09/i2, Orlando, FL, March 2009</i> [PMID ] </p> <p> <b>ZEST (vs PES), 2009 : </b> Park DW, Kim YH, Yun SC, Kang SJ, Lee SW, Lee CW, Park SW, Seong IW, Lee JH, Tahk SJ, Jeong MH, Jang Y, Cheong SS, Yang JY, Lim DS, Seung KB, Chae JK, Hur SH, Lee SG, Yoon J, Lee NH, Choi YJ, Kim HS, Kim KS, Kim HS, Hong TJ, Park HS, Park SJComparison of Zotarolimus-Eluting Stents With Sirolimus- and Paclitaxel-Eluting Stents for Coronary Revascularization The ZEST (Comparison of the Efficacy and Safety of Zotarolimus-Eluting Stent with Sirolimus-Eluting and PacliTaxel-Eluting Stent for Coronary Lesions) Randomized Trial. <i>J Am Coll Cardiol 2010 Oct 5;56:1187-95</i> [PMID 20883925] 10.1016/j.jacc.2010.03.086 </p> <p> <b>ISAR-TEST-4 (biodegradable polymer), 2009 : </b> Byrne RA, Kastrati A, Kufner S, Massberg S, Birkmeier KA, Laugwitz KL, Schulz S, Pache J, Fusaro M, Seyfarth M, Schömig A, Mehilli JRandomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. <i>Eur Heart J 2009 Aug 30;:</i> [PMID 19720642] </p> <p> <b>COMPARE, 2009 : </b> Kedhi E, Joesoef KS, McFadden E, Wassing J, van Mieghem C, Goedhart D, Smits PCSecond-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. <i>Lancet 2010 Jan 16;375:201-9</i> [PMID 20060578] 10.1016/S0140-6736(09)62127-9 </p> <p> <b>RESOLUTE All comers, 2010 : </b> Serruys PW, Silber S, Garg S, van Geuns RJ, Richardt G, Buszman PE, Kelbæk H, van Boven AJ, Hofma SH, Linke A, Klauss V, Wijns W, Macaya C, Garot P, Dimario C, Manoharan G, Kornowski R, Ischinger T, Bartorelli A, Ronden J, Bressers M, Gobbens P, Negoita MComparison of Zotarolimus-Eluting and Everolimus-Eluting Coronary Stents. <i>N Engl J Med 2010 Jun 16;:</i> [PMID 20554978] 10.1056/NEJMoa1004130 </p> <p> <b>RESOLUTE All comers, 2010 : </b> Silber S, Windecker S, Vranckx P, Serruys PWUnrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial. <i>Lancet 2011 Apr 1;:</i> [PMID 21459430] 10.1016/S0140-6736(11)60395-4 </p>